SEC Comment Letter 0000000000-23-013348 to Syndax Pharmaceuticals Inc (SNDX) (CIK 0001395937) (SNDX)
Syndax Pharmaceuticals Inc (SNDX) (CIK 0001395937)
Date: Dec. 7, 2023 · CIK: 0001395937 · Accession: 0000000000-23-013348
AI Filing Summary & Sentiment
File numbers found in text: 001-37708
Letter
United States securities and exchange commission logo December 7, 2023 Keith Goldan Chief Financial Officer Syndax Pharmaceuticals Inc 35 Gatehouse Drive, Building D, Floor 3 Waltham, Massachusetts 02451 Re:Syndax Pharmaceuticals Inc Form 10K for Fiscal Year Ended December 31, 2022 File No. 001-37708 Dear Keith Goldan: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
December 7, 2023
Keith Goldan
Chief Financial Officer
Syndax Pharmaceuticals Inc
35 Gatehouse Drive, Building D, Floor 3
Waltham, Massachusetts 02451
Re:Syndax Pharmaceuticals Inc
Form 10K for Fiscal Year Ended December 31, 2022
File No. 001-37708
Dear Keith Goldan:
We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences